Dexpramipexole hydrochloride hydrate | CAS# 908244-04-2 (hydrate) | Amyotrophic Lateral Sclerosis (ALS)

MedKoo Cat#: 413625 | Name: Dexpramipexole hydrochloride hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexpramipexole, also known as KNS-760704, is an orally administered drug candidate shown to selectively and significantly lower eosinophil counts in human blood and tissue. Dexpramipexole is the enantiomer of pramipexole. It is a low molecular weight, orally bioavailable, water-soluble small molecule with linear pharmacokinetics. Dexpramipexole (DPX) easily crosses the blood brain barrier (BBB) and exerts antioxidative properties by reducing ROS production, while the role of DPX in ferroptosis after ICH remains elusive.

Chemical Structure

Dexpramipexole hydrochloride hydrate

CAS#908244-04-2 (2HCl hydrate)

Theoretical Analysis

MedKoo Cat#: 413625

Name: Dexpramipexole hydrochloride hydrate

CAS#: 908244-04-2 (2HCl hydrate)

Chemical Formula: C10H21Cl2N3OS

Exact Mass: 0.0000

Molecular Weight: 302.26

Elemental Analysis: C, 39.74; H, 7.00; Cl, 23.46; N, 13.90; O, 5.29; S, 10.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

104632-27-1 (2HCl) 104632-28-2 (free base) 908244-04-2 (2HCl hydrate)

Synonym

Dexpramipexole 2HCl; KNS760704; KNS 760704; KNS-760704; Dexpramipexole dihydrochloride; R-Pramipexole

IUPAC/Chemical Name

(R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride hydrate

InChi Key

APVQOOKHDZVJEX-LSBIWMFESA-N

InChi Code

InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m1.../s1

SMILES Code

NC1=NC2=C(C[C@H](NCCC)CC2)S1.[H]Cl.[H]Cl.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 302.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Vieira FG, LaDow E, Moreno A, Kidd JD, Levine B, Thompson K, Gill A, Finkbeiner S, Perrin S. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLoS One. 2014 Dec 19;9(12):e91608. doi: 10.1371/journal.pone.0091608. eCollection 2014. PubMed PMID: 25526593; PubMed Central PMCID: PMC4272269. 2: Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Li H, Signore AP, Smith PJ, Gribkoff VK, Jonas EA. The mitochondrial complex V-associated large-conductance inner membrane current is regulated by cyclosporine and dexpramipexole. Mol Pharmacol. 2015 Jan;87(1):1-8. doi: 10.1124/mol.114.095661. Epub 2014 Oct 20. PubMed PMID: 25332381; PubMed Central PMCID: PMC4279080. 3: Wei D, Wu C, He P, Kerr D, Stecher S, Yang L. Chiral liquid chromatography-tandem mass spectrometry assay to determine that dexpramipexole is not converted to pramipexole in vivo after administered in humans. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Nov 15;971:133-40. doi: 10.1016/j.jchromb.2014.09.029. Epub 2014 Sep 30. PubMed PMID: 25289790. 4: Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T Jr, Archibald D. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):406-13. doi: 10.3109/21678421.2014.943672. Epub 2014 Aug 15. PubMed PMID: 25125035. 5: He P, Kerr D, Marbury T, Ries D, Farwell W, Stecher S, Dong Y, Wei D, Rogge M. Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function. J Clin Pharmacol. 2014 Dec;54(12):1383-90. doi: 10.1002/jcph.353. Epub 2014 Jul 3. PubMed PMID: 24965504; PubMed Central PMCID: PMC4241030. 6: Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J]. PubMed PMID: 24067398. 7: Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44-51. doi: 10.3109/17482968.2012.723723. Epub 2012 Sep 17. PubMed PMID: 22985432. 8: Corcia P, Gordon PH. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther Clin Risk Manag. 2012;8:359-66. doi: 10.2147/TCRM.S21981. Epub 2012 Aug 27. PubMed PMID: 22956874; PubMed Central PMCID: PMC3431958. 9: Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Mariggio MA, Onofrj M, Thomas A, Li H, Mangold JE, Signore AP, Demarco U, Demady DR, Nabili P, Lazrove E, Smith PJ, Gribkoff VK, Jonas EA. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11. doi: 10.1016/j.brainres.2012.01.046. Epub 2012 Jan 28. PubMed PMID: 22364637; PubMed Central PMCID: PMC3746080. 10: Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6. doi: 10.1038/nm.2579. PubMed PMID: 22101764. 11: Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20. Review. PubMed PMID: 21154151. 12: Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51(8):1177-85. doi: 10.1177/0091270010379412. Epub 2010 Oct 19. PubMed PMID: 20959524.